HighPoint Advisor Group LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.8% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 7,868 shares of the company’s stock after selling 663 shares during the period. HighPoint Advisor Group LLC’s holdings in Eli Lilly and were worth $654,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Acrospire Investment Management LLC grew its holdings in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the period. MPS Loria Financial Planners LLC bought a new position in Eli Lilly and during the second quarter worth about $128,000. San Francisco Sentry Investment Group CA bought a new position in Eli Lilly and during the second quarter worth about $129,000. Point72 Asia Hong Kong Ltd grew its holdings in Eli Lilly and by 237.4% during the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after purchasing an additional 1,239 shares during the period. Finally, Shine Investment Advisory Services Inc. bought a new position in Eli Lilly and during the second quarter worth about $148,000. Institutional investors and hedge funds own 76.30% of the company’s stock.

Shares of Eli Lilly and Company (NYSE:LLY) opened at $86.08 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Company has a 1 year low of $72.68 and a 1 year high of $89.09. The firm has a market cap of $95,321.80, a P/E ratio of 21.17, a PEG ratio of 1.79 and a beta of 0.35.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same period in the previous year, the business earned $0.88 earnings per share. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. analysts predict that Eli Lilly and Company will post 4.22 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be given a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.61%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s payout ratio is presently 98.58%.

In other news, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the sale, the senior vice president now directly owns 54,885 shares in the company, valued at $4,729,989.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 651,088 shares of company stock valued at $56,439,586. 0.20% of the stock is owned by company insiders.

A number of equities analysts recently commented on LLY shares. Jefferies Group reiterated a “buy” rating and set a $89.00 price target on shares of Eli Lilly and in a report on Monday, September 11th. BMO Capital Markets reiterated an “underperform” rating and set a $71.00 price target (down previously from $73.00) on shares of Eli Lilly and in a report on Wednesday, September 6th. Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their price target for the stock from $84.23 to $88.00 in a report on Tuesday, October 10th. Piper Jaffray Companies reiterated an “overweight” rating and set a $105.00 price target (up previously from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. Finally, Berenberg Bank reiterated a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a report on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company. Eli Lilly and presently has an average rating of “Hold” and a consensus target price of $90.25.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/eli-lilly-and-company-lly-shares-sold-by-highpoint-advisor-group-llc/1772676.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.